U.S.

care prvdrs wrt mr thn nn mlln prscriptons

for Ozempic, Wegovy and diabetes and obesity

drugs the last thr mnths of 2022, accrdng to a

new rlsd Wednesday.

The rprt, from analytics firm Trilliant Health, that qurtrly

prscrptns for those increased 300% between

2020 and the end of last year.

Novo Nordisk’s wkly dbts injctn Ozempc accuntd for more than

65% of ttl prscrptns as of the of 2022, and was prmrly

prscrbd off-label for its ability to patients lose

The dt further confirms the in dmnd for that of

drugs, which have fuld a frnzy amng Americans and on Wall

Street for their ability to significant weight .

Those trtmnts, known as GLP-1s, mimic a hrmn in the gut to
suppress a person’s appetite.

But the rate of prscrptn vlms will lrgly dpnd on whether

manufacturers of those drugs, Novo Nordisk Eli Lilly,

can reslve widsprd supply shrtgs affctng most of their trtmnts
in the U.S., amng other factors, accrdng to the rprt.